bluebird bio and apceth Biopharma sign commercial manufacturing agreement

bluebird bio and apceth Biopharma entered a strategic manufacturing agreement for European commercial production of bluebird bio's Lenti-D and LentiGlobin gene therapy products at apceth's GMP facility in Munich.

“By partnering with multiple organizations, including our valued partner apceth Biopharma, we are able to develop integrated capabilities in manufacturing.”biotechnewswire.ai

• 2 sources
• biotechnewswire.aibluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing AgreementDec 15, 2016
• emjreviews.comBluebird Bio and Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement - European Medical JournallouisakewellDec 19, 2016

Summarized from public sources; check the original articles before acting on it.